CC
LAB icon

Clearline Capital’s Standard BioTools LAB Stock Holding History

Clearline Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-232,595
Closed -$1.4M – 131
2020
Q4 		$1.4M Sell
232,595
-74,234
-24% -$488K 0.31% 64
2020
Q3 		$2.28M Buy
+306,829
New +$2.12M 0.6% 46

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Clearline Capital's LAB Position: Q1 2021 in Review

Clearline Capital sold out of Standard BioTools (LAB) in Q1 2021, closing a stake of 232,595 shares — an estimated $1.4M sold.

Clearline Capital first reported a position in LAB in Q3 2020 and held it in 2 quarters. The position peaked at $2.28M in Q3 2020. 138 funds tracked by Wall St. Rank hold LAB as of Q1 2021.

  • Clearline Capital reported no remaining Standard BioTools position as of Q1 2021 after selling out during the quarter.
  • Clearline Capital sold 232,595 Standard BioTools shares in Q1 2021, an estimated $1.4M.
  • Clearline Capital first reported a position in Standard BioTools in Q3 2020 and held it in 2 quarters.
  • Clearline Capital's Standard BioTools position peaked at $2.28M in Q3 2020.
  • 138 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2021.

Based on Clearline Capital's 13F filing for Q1 2021, filed 17 May 2021.